Efficacy and safety study of frexalimab (SAR441344) in adults with nonrelapsing secondary progressive Multiple Sclerosis

Is your MS progressing?

There are few effective treatment options available for people with non-relapsing, secondary progressive MS. Frexalimab is a monoclonal antibody that binds to and disrupts a protein called CD40L, which is found on certain white blood cells and is necessary for them to function. Frexalimab is being studied as a treatment for people with secondary progressive MS in a randomized, placebo controlled clinical trial (Freviva).

This is a Phase 3 trial, designed to see whether the investigational medicine works in this group of patients and whether it is safe. Participants will be randomly selected to receive placebo or the study drug; each participant has a 2 out of 3 chance of getting the active medication. Neither you nor your doctor will know which treatment you received until after the study is over. The study will provide study drug (a monthly infusion), blood testing and MRIs throughout the entire study, and study participation will last approximately 4.5 years.